NCT04024878 — NeoVax neoantigen vaccine trial
NeoVax With Nivolumab in Patients With Ovarian Cancer
Registry record
| Registry ID | NCT04024878 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | United States Department of Defense, National Cancer Institute (NCI) |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Ovarian Cancer |
| Enrollment | 22 participants (target) |
| Start date | 2020-11-20 |
| Primary completion | 2025-04-30 |
| Last registry update | 8 Oct 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04024878), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04024878?
NCT04024878 (NeoVax With Nivolumab in Patients With Ovarian Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT04024878 recruiting?
As of the 2026-10-08 registry update, NCT04024878 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04024878?
The lead sponsor is Dana-Farber Cancer Institute. Collaborators: United States Department of Defense, National Cancer Institute (NCI).
What condition does NCT04024878 study?
The registered condition is Ovarian Cancer. Primary completion is listed as 2025-04-30.
Are results available for NCT04024878?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04024878.
Back to the full neoantigen vaccine trial tracker — 106 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.